Secondary Logo

Institutional members access full text with Ovid®

Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease

Ma, Danning, PharmD; Wong, Wendy, PharmD; Aviado, Jeremie, BS; Rodriguez, Cesar, BS; Wu, Helen, PharmD

American Journal of Gastroenterology: February 2019 - Volume 114 - Issue 2 - p 352–354
doi: 10.1038/s41395-018-0368-1
BRIEF COMMUNICATIONS
Buy

INTRODUCTION: Infliximab for inflammatory bowel disease (IBD) is FDA-approved to be administered 2 h or more. We adopted a new protocol to infuse infliximab over 1 h and in this study, we aimed to determine the safety of a 1-h infusion.

METHODS: This retrospective cohort included adult IBD patients who received infliximab between June and December 2017 and compared reaction rates of 1-h maintenance infusions to that of 2-h maintenance infusions.

RESULTS: A total of 551 infusions were administered to 179 patients. The infusion groups demonstrated no significant differences in reaction rates.

CONCLUSIONS: Infliximab infusion over 1 h is well-tolerated.

Department of Clinical Pharmacy, University of California, San Francisco, CA, USA

Correspondence: Helen Wu Pharm.D. E-mail: Helen.Wu@ucsf.edu.

Received July 12, 2018

Accepted September 05, 2018

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website